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Background: Radiotherapy (RT) is widely used in the treatment of pancreatic cancer. Currently, recommendation
has been given for the delineation of the clinical target volume (CTV) in adjuvant RT. Based on recently reviewed
pathologic data, the aim of this study is to propose criteria for the CTV definition and delineation including elective
nodal irradiation (ENI) in the preoperative and definitive treatment of pancreatic cancer.
Methods: The anatomical structures of interest, as well as the abdominal vasculature were identified on
intravenous contrast-enhanced CT scans of two different patients with pancreatic cancer of the head and the body.
To delineate the lymph node area, a margin of 10 mm was added to the arteries.
Results: We proposed a set of guidelines for elective treatment of high-risk nodal areas and CTV delineation.
Reference CT images were provided.
Conclusions: The proposed guidelines could be used for preoperative or definitive RT for carcinoma of the head
and body of the pancreas. Further clinical investigations are needed to validate the defined CTVs.
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Surgery is the only potentially curative modality for patients
with clinically localized and operable pancreatic cancer [1].
Combined modality therapy compared to surgery alone has
shown an advantage in terms of overall survival and should
be considered for adjuvant treatment of resectable cancer
patients [2-5]. Chemo-radiation represents a treatment
option for patients with unresectable disease [6].
In particular, in our previous systematic review, an im-
provement of surgical resectability and in overall survival
has been shown for patients with unresectable tumor trea-
ted with neoadjuvant chemo-radiotherapy and surgical re-
section (median survival: 16 – 32 months) [7]. Given the
5-year survival results (18-41%; median: 36%) in that* Correspondence: gmacchia@rm.unicatt.it
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reproduction in any medium, provided the orpublication on patients treated with preoperative radio-
therapy (RT) [7], patients with unresectable pancreatic can-
cer without disease progression after chemo-radiotherapy
should be considered for radical surgery and could be
regarded as potentially curable.
Although there is no consensus concerning the elective
nodal irradiation (ENI) in pancreatic cancer RT [8], it
could be justified in a treatment with curative intent.
Moreover, a high frequency of lymphatic spread (60–80%)
was reported in head pancreatic cancer [9,10] and a high
rate of local and nodal failure was noted in pathologic and
clinical analyses (up to 75%) [11-13]. Based on these data,
the prognosis of these patients could be theoretically
improved reaching a higher local control and reducing the
nodal recurrence rate [11-13], as already shown in resect-
able pancreatic carcinoma treated with ENI and concur-
rent chemotherapy (local recurrence rate with or without
ENI: 0-13% vs 25%, respectively) [14,15].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as kidneys, liver, small bowel, stomach, duodenum
and spinal cord remain the main problems of abdominal
radiotherapy, especially when large volume is treated.
Therefore, CT-based definition of the clinical target volume
(CTV) and 3D treatment planning (3D-CRT), thus redu-
cing the dose to OARs, is strongly recommended and is
currently considered the standard approach [8,16].
Further advantages can be achieved by intensity modu-
lated radiotherapy (IMRT) [17], as well as by 4D treatment
planning [18]. For both 3D and IMRT treatment planning,
a proper knowledge, definition and delineation of CTV is
required. Moreover, this issue became particularly relevant
for IMRT-based treatment planning based on the dose
gradients close to the planning target volume (PTV). For
this reason, standardized contouring guidelines to ensure
the adequacy of the CTV should be provided.
Few indications for the CTV definition of elective treat-
ment in adjuvant or definitive radiotherapy have been
given [19-22]. Generally, the treatment target volume de-
lineation was related to the location of the primary disease
and to the status of lymph node involvement [16]. Cur-
rently, no recommendations based on modern imaging
modalities are available for preoperative or definitive RT.
Moreover, several anatomic and pathologic studies have
been conducted to identify lymphatic network and high
risk areas of lymph node involvement [23-27] and to de-
fine the pattern of perineural invasion of pancreatic cancer
[27-29]. Concerning lymphatic drainage, a rich communi-
cation between the anterior surface of the head of the pan-
creas, the common hepatic artery, the celiac trunk origin
and the superior mesenteric artery was described. As wellTable 1 High risk lymph node regions of the head pancreatic
Pancreatic head tumor
Lymph node group JPS Classification [32]
Infrapyloric lymph nodes Group 6
Common hepatic artery lymph nodes Group 8
Celiac trunk lymph nodes Group 9
Hepatoduodenal ligament lymph nodes Group 12
Posterior pancreaticoduodenal lymph nodes Group 13
Superior mesenteric artery lymph nodes Group 14
Paraaortic lymph nodes Group 16
Anterior pancreaticoduodenal lymph nodes Group 17
* also include any visible nodes (lower axis> 1 cm and/or FDG- avid on PET) plus a
Lymph nodes nomenclature is based on the General Rules for Cancer of the Pancre
interest and the abdominal blood vessels of reference were identified for each lympas a lymphatic pathway from the body and the tail of pan-
creas was shown around the splenic blood vessels and the
inferior pancreatic artery up to the lymph nodes situated
on the left side of the celiac trunk and the superior mesen-
teric artery [23,24]. The extent of perineural invasion has
been also demonstrated in a number of pathologic studies,
often showing lymphatic emboli and neural invasions in
the soft tissue adherent to the vessels and near to the
metastatic nodes [27-29]. The close embryologic develop-
ment relationship of lymphatic and nervous structures
could justify the dual pathway of dissemination of pancre-
atic cancer along peripancreatic connective tissues [30].
In particular, a review of 18 pathologic reports (reported
on 5954 resectable pancreatic cancer patients treated with
radical surgery) was recently conducted to evaluate the prob-
ability of lymph node metastases and to define the high risk
lymph nodal regions, related to the primary tumor site (head
or body/tail of pancreas) [31]. Based on these reviewed
pathologic data, the aim of this study is to propose criteria
for CTV definition and delineation including ENI in the pre-
operative or exclusive treatment of pancreatic cancer.
Methods
Clinical target volume definition and delineation
Based on the review of Sun et al. [31], the high risk lymph
node regions, related to the head and body/tail of the pan-
creas, were defined as ENI areas. Particularly, according to
the reviewed data, each lymph nodal region with a prob-
ability of involvement≥ 3% was considered to be at clinic-
ally significant risk and proposed as an ENI area.
All lymph nodal nomenclature is based on the General
Rules for Cancer of the Pancreas published by the Japancancer
% Recommended margins *
7.2 10 mm margin around the inferior border of the pylorus
9.8 10 mm margin around the common hepatic artery, from the
origin of the artery (correspond to the superior border of the
pancreas), on the anterior surface of the portal vein upper to
the hilum of the liver
3.7 10 mm margin around the celiac trunk
7.9 10 mm margin around the portal vein segment that runs
anteromedial to the inferior vena cava and between the porta
hepatis of the liver and the superior part of the duodenum
32.3 10 mm margin around the inferior - posterior
pancreaticoduodenal artery
15.8 10 mm margin around the origin of superior mesenteric artery
10.9 10 mm margin around the abdominal aorta, between the celiac
artery and the inferior mesenteric artery
19.8 10 mm margin around the superior - anterior
pancreaticoduodenal artery
margin of 10 mm.
as published by the Japan Pancreas Society (JPS). The anatomical structures of
h node region.
Figure 1 (See legend on next page.)
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Figure 1 Anatomical structures for the high risk lymph nodal regions of the head pancreatic cancer. Transverse CT slices through high
risk lymph node regions of the head pancreatic cancer from cranial to caudal direction. The abdominal artery and the anatomical structures were
identified as a surrogate target for lymph node regions. A margin of 10 mm was added to the artery to delineate lymph node area, including the
soft tissue with lymphatic and neural plexus. CTV was formed by the union of the identified lymph node areas. Abbreviations: Ao =Aorta;
APLn=Anterior Pancreaticoduodenal Lymph nodes; CBD=Common Bile Duct; CeLn =Celiac Lymph nodes; CHA=Common Hepatic Artery;
ChLn=Common hepatic and hepatoduodenal ligament Lymph nodes; CT = Celiac Trunk; 1st D = first part of Duodenum; GdA=Gastroduodenal
Artery; InLn = Infrapyloric Llymph nodes; IPdA= Inferior Pancreaticoduodenal Artery; IVC = Inferior Vena Cava; JA = Jejunal Artery; MCA=Medial
Colic Artery; PaLn = Paraaortic Lymph nodes; Pb = Pancreatic body; Ph = Pancreatic head; Pt = Pancreatic tail; Pyl = Pylorus; PPLn= Posterior
Pancreaticoduodenal Lymph nodes; PV = Portal Vein; 2nd D= second part of Duodenum; SMA= Superior Mesenteric Artery; SMLn= Superior
Mesenteric Lymph nodes; SMV= Superior Mesenteric Vein; SPdA= Superior Pancreaticoduodenal Artery; SpV = Splenic Vein; * = pillar of the
diaphragm.
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risk lymph nodal regions for head and body/tail pan-
creatic carcinoma.
Thin-cut dynamic multiphase helical CT scan of the
was performed in two different patients for the delinea-
tion of CTV in the treatment of the head and the body
pancreas adenocarcinoma, respectively. CT scans were
performed with a high-speed scanner (CT Hi Speed Nx/i
Pro; 2-slice; GE Medical System, Milwaukee,WI, USA)
and were acquired with 3 mm thickness and 9 mms_1
table speed. Abdominal blood vessels and anatomical
structures were identified as a surrogate region of inter-
est for the delineation of high risk lymph nodal regions
(Table 1). Correct localization of each anatomical struc-
ture was identified by the radiologist and the radiation
oncologist by dynamic observation during all contrasto-
graphic phases (early arterial, arterial, portal and late
phases) and delineated on late contrastographic phase.
Based on pathologic studies [27-29], to delineate a
lymph node area, a margin of 10 mm was added to the
artery including the soft tissue with the lymphatic and
neural plexus. This margin was not extended into the
other normal tissue or structures, e.g. the vertebral body
(Figures 1 and 2).
Other modifications were then made. In view of the
proximal location of the hepatoduodenal ligament and
the common hepatic artery, only one lymph node area
(Group 8 and 12) was delineated for both structures
(light violet area, Figures 1 and 2).
For lymph nodes around the superior mesenteric ar-
tery (Group 14), we included the soft tissue around the
vessel based on the demonstrated subclinical metastatic
rate [27-31]; because a moderate metastatic rate of the
subgroup 14c (lymph nodes at the root of the medial
colic artery) and the subgroup 14d (lymph nodes at the
root of the jejunal artery) was observed [27-31], we sug-
gested to include also the soft tissue around these vessels
in the contouring (violet area, Figures 1 and 2).
Concerning the paraaortic lymph nodes (Group 16),
pathologic reports [25,26,31,33] showed that the majority
of positive lymph nodes was in the areas between theceliac artery and the inferior mesenteric artery, wherever
the primary tumors were situated. Therefore, only this
area was included in the contouring (red area, Figures 1
and 2). Moreover, in the area between the celiac artery
and the inferior mesenteric artery, the positive lymph
nodes were mainly located anterior to the abdominal aorta
and between the abdominal aorta and the inferior vena
cava. Therefore, the contouring was extended anteriorly,
laterally and posteriorly to these vessels with the exception
of the lateral side of the inferior vena cava (red area,
Figures 1 and 2).
After all the ENI areas were delineated, the CTV was
defined by the union of the identified areas as shown in
Figure 3.
Results
Two patients with unresectable pancreatic cancer of the
head and body/tail were included in this study. Two dif-
ferent CTVs have been defined according to the
reviewed data and the different tumor location in the
head or body- tail of the pancreas [31]. The reference
images, produced at 10 mm of distance between each
slice, are shown for both tumor sites in Figure 3a and
3b, respectively.
For tumors located in the head of the pancreas, the
CTV was defined by the union of the lymphatic areas
around the infrapyloric region (Group 6), the common
hepatic artery (Group 8), the celiac trunk (Group 9), the
hepatoduodenal ligament (Group 12), the posterior pan-
creaticoduodenal artery (Group 13), the superior mesen-
teric artery (Group 14), the paraaortic area (Group 16)
and the anterior pancreaticoduodenal artery (Group 17)
(blue areas, Figure 3a).
In patients with pancreatic body- tail tumor lymph
nodes around the common hepatic artery (Group 8), the
celiac trunk (Group 9), the splenic artery and the ilus of
spleen (Group 10 and 11), the hepatoduodenal ligament
(Group 12), the superior mesenteric artery (Group 14),
the paraaortic region (Group 16), the inferior body area
(Group 18) were included in the CTV (blue areas,
Figure 3b).
Figure 2 (See legend on next page.)
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Figure 2 Anatomical structures for the high risk lymph nodal regions of the body/tail pancreatic cancer. Transverse CT slices through
high risk lymph node regions of the body/tail pancreatic cancer from cranial to caudal direction. The abdominal artery and the anatomical
structures were identified as a surrogate target for lymph node regions. A margin of 10 mm was added to the artery to delineate lymph node
area, including the soft tissue with lymphatic and neural plexus. Abbreviations: Ao =Aorta; CeLn =Celiac Lymph nodes; CHA=Common Hepatic
Artery; ChLn=Common hepatic and hepatoduodenal ligament Lymph nodes; CT = Celiac Trunk; 1st D = first part of Duodenum; Ga=Gallbladder;
IBLn = Inferior Body Lymph nodes; IMA= Inferior Mesenteric Artery; InLn = Infrapyloric Lymph nodes; IPA = Inferior Pancreatic Artery; IVC = Inferior
Vena Cava; JA = Jejunal Artery; MCA=Medial Colic Artery; PaLn = Paraaortic Lymph nodes; Ph = Pancreatic head; Pyl = Pylorus; PV = Portal Vein; 2nd
D= second part of Duodenum; SpA= Splenic Artery; SpLn = hilus of the spleen and Splenic Lymph nodes; SMA= Superior Mesenteric Artery;
SMLn= Superior Mesenteric Lymph nodes; SMV= Superior Mesenteric Vein; 3rd D= third part of Duodenum; * = pillar of the diaphragm.
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into the CTV, with a 3 cm margin in the pancreatic
tissue.
More details about the anatomical structures of interest
and the abdominal blood vessels of reference for each
lymph node region were described in Tables 1 and 2.
Discussion
The aim of this investigation was to propose standard
criteria for the CTV definition and delineation in the
preoperative or exclusive treatment of pancreatic cancer,
with particular attention to elective lymph node areas.
It must be admitted that ENI is controversial and may
be considered questionable [8]. In fact, palliative RT has
been shown to be effective even without prophylactive
nodal irradiation [34].
Furthermore, in order to increase the resectability, a
dose escalation to the Gross Tumor Volume (GTV)
more than a prophylactic dose may be required, as well
as the inclusion of lymph nodes in the irradiated volume
may be associated with increased toxicity and represent
a limit for concurrent chemotherapy [35,36].
However, we must recognize that a high incidence of
local and nodal failure was noted in pathologic and clin-
ical analyses [11-13]. Based on these data, the prognosis
of patients with pancreatic carcinoma remains condi-
tioned by low local control and by a high nodal recur-
rence rate (21-47%) [11-13]. Moreover, the use of new
technologies (IMRT, 4D-RT) could reduce the risk of
toxicity related to ENI, and allow dose-escalation studies
to improve the local control rate [17,18].
Guidelines for the delineation of ENI were proposed by
Brunner et al. [19] and concerned only the treatment of
head pancreatic carcinoma. Based on pathologic evalu-
ation of 175 patients with ductal head pancreatic carcin-
oma who underwent radical pancreatoduodenectomy, the
study confirmed the high probability of lymphatic spread
and the need of the elective irradiation of regional and
paraaortic lymphatic areas. Indeed, the total incidence of
regional lymph node metastasis was 76% (133/175 cases)
and the posterior pancreaticoduodenal area, superior and
inferior pancreatic head margin, anterior pancreaticoduo-
denal area, hepatoduodenal ligament, superior pancreaticbody and superior mesenteric artery were identified as
high-risk lymphatic involvement areas and selected for
elective treatment [19].
In our study, based on the recent pathologic data re-
view from Sun et al. [31], criteria for the CTV definition
and delineation were proposed. One potential limitation
of our proposal could be that many anatomical data are
derived from Japanese studies. Unfortunately, since the
unavailability at moment of large series in Europe, we
needed to refer to the most relevant published scientific
data.
A cut-off value of 3% risk of lymph node involvement,
as reported in Sun et al. [31], was used to identify lymph
nodal regions to be included in the CTV. This cut-off
value may seem relatively low. However, in the Sun’s
study the lymph node metastatic incidence was patho-
logically evaluated in resectable low-stage carcinomas,
while radiation therapy is often used in patients with
advanced disease. Therefore, we considered the 3% cut-
off value appropriate. Moreover, as is shown in the
Tables 1 and 2, if a “classical” cut off of 10-15% was been
chosen, some commonly considered high risk lymph
node areas in post-operative setting (as common hepatic
artery lymph nodes, hepatoduodenal ligament lymph
nodes, celiac trunk lymph nodes, paraaortic lymph nodes
for head tumors and hilus of the spleen lymph nodes for
body/tail tumors) would been excluded.
A 10 mm margin was added around the arteries to de-
fine the lymphatic area, according to pathologic studies
[27-29], where tumor infiltration was demonstrated in
the soft tissue area with lymphatic and neural plexus,
10 mm around the artery. Furthermore, previous guide-
lines for pelvic lymph nodes delineation using IMRT,
showed the possibility to cover 94% of nodes using a
10 mm margin around arteries [37].
Looking at these criteria, for tumors located in the
head of the pancreas, we proposed the inclusion in the
elective CTV of the following nodal areas: the infrapylo-
ric lymph nodes (Group 6), the lymph nodes around the
common hepatic (Group 8) and the hepatoduodenal
ligament (Group 12), the celiac trunk lymph nodes
(Group 9), the posterior pancreaticoduodenal lymph
nodes (Group 13), the superior mesenteric lymph nodes
Figure 3 (See legend on next page.)
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Figure 3 CTV delineation in the treatment of the head and the body pancreas adenocarcinoma. Transverse CT slices through high risk
lymph node regions of the head (a) and body/tail (b) pancreatic cancer from cranial to caudal direction. CTV was formed by the union of the
identified lymph node areas (blue area).
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the anterior pancreaticoduodenal lymph nodes (Group
17). For patients with pancreatic body and tail disease,
we included the lymph nodes around the common hep-
atic artery (Group 8), the celiac trunk (Group 9), the
splenic artery and the ilus of spleen (Group 10 and 11),
the hepatoduodenal ligament (Group 12), the superior
mesenteric artery (Group 14), the paraaortic region
(Group 16), and the inferior body area (Group 18).
Although these indications are quite comparable to
that reported by Brunner et al. [19], concerning the
treatment of the head pancreatic adenocarcinoma,
they appear to be partly different from those com-
monly reported by the currently reference literature
[8,38]. Particularly, lymph nodes around the common
hepatic artery (Group 8) and the hepatoduodenal liga-
ment (Group 12) were included in the CTV also for
body- tail tumors.
In this study we proposed a method for CTV defin-
ition and delineation in the preoperative and definitive
treatment of pancreatic cancer. Based on our institu-
tional evaluation and a previous published study [39] a
margin of 12 mm, 7 mm and 5 mm, in the craniocaudal,
lateral and anterior, and posterior direction, were re-
spectively considered appropriated from the CTV to theTable 2 High risk lymph node regions of the body/tail pancre
Pancreatic body/tail tumor
Lymph node group JPS Classification [32] %
Infrapyloric lymph nodes Group 6 3.3
Common hepatic artery lymph nodes Group 8 15.1
Celiac trunk lymph nodes Group 9 9.6
Hilus of the spleen lymph nodes Group 10 4.1
Splenic artery lymph nodes Group 11 35.6
Hepatoduodenal ligament lymph nodes Group 12 8.2
Superior mesenteric artery lymph nodes Group 14 9.6
Paraaortic lymph nodes Group 16 16.4
Inferior body lymph nodes Group 18 24.7
* also include any visible nodes (lower axis> 1 cm and/or FDG- avid on PET) plus a
Lymph nodes nomenclature is based on the General Rules for Cancer of the Pancre
interest and the abdominal blood vessels of reference were identified for each lympPTV. Moreover, given that no close assumption can
been taken about comparison with standard technique
in term of impact on OAR irradiation, by using this
method we strongly recommend a careful evaluation of
DVH, especially if concurrent Gemcitabine has been
administered.
Furthermore, since a large inter-observer variance has
been shown [40], if standardized anatomical structures
of reference are defined for each lymph node regions
and recognized in the individual patient, a more repro-
ducible and a tailored patient volume may be obtained.
Conclusions
Based on the incidence of lymph node metastases, we
developed a proposal for target contouring in pancreatic
cancer. This proposal may represent a basis for a multi-
institutional consensus on contouring guidelines in these
tumors. However, in order to validate these guidelines
through patterns of failures studies, in our center a dose
escalation study using a Volumetric-Modulated Arc
Therapy (VMAT) technique with Simultaneous Inte-
grated Boost (SIB) was designed. After the treatment,
patients will be re-evaluated by FDG-PET/CT scan and
CT scan with contrast every 3 months for 3 years and
every 6 months in the following 2 years.atic cancer
Recommended margins *
10 mm margin around the inferior border of the pylorus
10 mm margin around the common hepatic artery, from the origin of
the artery (correspond to the superior border of the pancreas), on the
anterior surface of the portal vein upper to the hilum of the liver
10 mm margin around the celiac trunk
10 mm margin around each visible splenic vessel
10 mm margin around the splenic artery
10 mm margin around the portal vein segment that runs anteromedial
to the inferior vena cava and between the porta hepatis of the liver and
the superior part of the duodenum
10 mm margin around the origin of superior mesenteric artery
10 mm margin around the abdominal aorta, between the celiac
artery and the inferior mesenteric artery
10 mm margin around the inferior pancreatic artery
margin of 10 mm.
as published by the Japan Pancreas Society (JPS). The anatomical structures of
h node region.
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